Prevalence, clinico-pathological features and outcomes of ‘double-hit’ high-grade B-cell non-Hodgkins lymphoma (NHL): a single institution experience
ANNALS OF ONCOLOGY(2016)
Abstract
BackgroundMYC/BCL2 (or MYC/BCL6) double hit lymphoma (DHL) is defined as a large B-cell lymphoma with concurrent translocations. Several studies indicate that up to 10% of diffuse large B-cell lymphomas (DLBCLs) harbouring a MYC rearrangement will have a poorer prognosis, worse still when present with a BLC2/6 rearrangement. Currently, there is a paucity of guidelines bridging together this data to decide the most effective therapy for DHL patients.MethodsFrom August 2013 to October 2015, all patients with high grade B-cell NHL who had tissue samples referred to the central pathology laboratory at St. James Hospital, Dublin were included for analysis. Patient demographics, clinical features, histopathological details, systemic therapy received and patient-related outcomes were recorded from electronic or paper medical records. All cases were reviewed by a consultant haematopathologist.Results152 cases of high-grade B-cell NHL were identified since FISH testing for MYC rearrangement commenced in St. James Hospital. 21 patients displayed MYC rearrangement, 9 of whom had a concurrent BCL2 rearrangement. One patient with MYC and BCL2 rearrangements also had a BCL6 rearrangement. These patients all had germinal centre cell of origin (GC COO) by Hans criteria. 4 patients with DHL had prior follicular lymphoma and 5 patients had no prior lymphoma. Patients were treated with varying regimens including standard or dose-intensified chemo-immunotherapy. All patients with DHL achieving a complete response (CR) were consolidated with transplantation (n = 5), both in first line and salvage settings. 2 patients underwent autologous transplantation and 3 underwent allogeneic transplantation. The 1-year survival for all DHL patients was 67%ConclusionsIn our study of all high-grade NHL, the frequency of DHL was 6%. All patients had GC COO by Hans criteria. We suggest considering referral of all patients with DLBCL for MYC-rearrangement testing at the time of initial diagnosis with consideration given to upfront dose-intensified chemotherapy and early haematogenous cell transplantation referral, once DHL status is known.Legal entity responsible for the study: N/AFundingN/ADisclosureAll authors have declared no conflicts of interest. BackgroundMYC/BCL2 (or MYC/BCL6) double hit lymphoma (DHL) is defined as a large B-cell lymphoma with concurrent translocations. Several studies indicate that up to 10% of diffuse large B-cell lymphomas (DLBCLs) harbouring a MYC rearrangement will have a poorer prognosis, worse still when present with a BLC2/6 rearrangement. Currently, there is a paucity of guidelines bridging together this data to decide the most effective therapy for DHL patients. MYC/BCL2 (or MYC/BCL6) double hit lymphoma (DHL) is defined as a large B-cell lymphoma with concurrent translocations. Several studies indicate that up to 10% of diffuse large B-cell lymphomas (DLBCLs) harbouring a MYC rearrangement will have a poorer prognosis, worse still when present with a BLC2/6 rearrangement. Currently, there is a paucity of guidelines bridging together this data to decide the most effective therapy for DHL patients. MethodsFrom August 2013 to October 2015, all patients with high grade B-cell NHL who had tissue samples referred to the central pathology laboratory at St. James Hospital, Dublin were included for analysis. Patient demographics, clinical features, histopathological details, systemic therapy received and patient-related outcomes were recorded from electronic or paper medical records. All cases were reviewed by a consultant haematopathologist. From August 2013 to October 2015, all patients with high grade B-cell NHL who had tissue samples referred to the central pathology laboratory at St. James Hospital, Dublin were included for analysis. Patient demographics, clinical features, histopathological details, systemic therapy received and patient-related outcomes were recorded from electronic or paper medical records. All cases were reviewed by a consultant haematopathologist. Results152 cases of high-grade B-cell NHL were identified since FISH testing for MYC rearrangement commenced in St. James Hospital. 21 patients displayed MYC rearrangement, 9 of whom had a concurrent BCL2 rearrangement. One patient with MYC and BCL2 rearrangements also had a BCL6 rearrangement. These patients all had germinal centre cell of origin (GC COO) by Hans criteria. 4 patients with DHL had prior follicular lymphoma and 5 patients had no prior lymphoma. Patients were treated with varying regimens including standard or dose-intensified chemo-immunotherapy. All patients with DHL achieving a complete response (CR) were consolidated with transplantation (n = 5), both in first line and salvage settings. 2 patients underwent autologous transplantation and 3 underwent allogeneic transplantation. The 1-year survival for all DHL patients was 67% 152 cases of high-grade B-cell NHL were identified since FISH testing for MYC rearrangement commenced in St. James Hospital. 21 patients displayed MYC rearrangement, 9 of whom had a concurrent BCL2 rearrangement. One patient with MYC and BCL2 rearrangements also had a BCL6 rearrangement. These patients all had germinal centre cell of origin (GC COO) by Hans criteria. 4 patients with DHL had prior follicular lymphoma and 5 patients had no prior lymphoma. Patients were treated with varying regimens including standard or dose-intensified chemo-immunotherapy. All patients with DHL achieving a complete response (CR) were consolidated with transplantation (n = 5), both in first line and salvage settings. 2 patients underwent autologous transplantation and 3 underwent allogeneic transplantation. The 1-year survival for all DHL patients was 67% ConclusionsIn our study of all high-grade NHL, the frequency of DHL was 6%. All patients had GC COO by Hans criteria. We suggest considering referral of all patients with DLBCL for MYC-rearrangement testing at the time of initial diagnosis with consideration given to upfront dose-intensified chemotherapy and early haematogenous cell transplantation referral, once DHL status is known.Legal entity responsible for the study: N/A In our study of all high-grade NHL, the frequency of DHL was 6%. All patients had GC COO by Hans criteria. We suggest considering referral of all patients with DLBCL for MYC-rearrangement testing at the time of initial diagnosis with consideration given to upfront dose-intensified chemotherapy and early haematogenous cell transplantation referral, once DHL status is known.
MoreTranslated text
Key words
lymphoma,clinico-pathological,double-hit,high-grade,b-cell,non-hodgkins
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined